data.xlsx

<br> The study was registered in and approved from the Medical Ethics Committee in the University of Kufa, college of medicine with reference: (MEC_13). The study protocol was registered in ClincialTrials.gov (identifier: <strong>NCT05398874</strong><strong>)</strong>. Participants were asked to sign a printed informed consent that explained the aim of study. This was a randomized double blinded clinical trial conducted in a private orthopaedic clinic in Al-Najaf Government in Iraq from November 1st 2021 to June 1st 2022. The doctor of clinic defined the patients that can be enrolled in the study and informed them about aim of study and take oral and written consent from them. Then the researcher randomized patients into two groups using simple randomization (Block size 4 (2A, 2B), allocation:1:1). The doctor and patients did not know in which group they were categorized. Group A received EGb-761 120mg twice daily while group B received placebo (starch) capsule <br> Clinical assessment was done before starting treatment, after two weeks, four weeks, and eight weeks by KOOS questionnaire. KOOS includes 42 items divided into 5 subscales. These are pain, symptoms, ADL, sport and recreational activity, and finally QOL associated with knee activity <br>